Cravens & CO Advisors, LLC Regeneron Pharmaceuticals, Inc. Transaction History
Cravens & CO Advisors, LLC
- $135 Billion
- Q2 2024
A detailed history of Cravens & CO Advisors, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Cravens & CO Advisors, LLC holds 1,234 shares of REGN stock, worth $1.02 Million. This represents 0.96% of its overall portfolio holdings.
Number of Shares
1,234
Previous 1,291
4.42%
Holding current value
$1.02 Million
Previous $1.24 Billion
4.38%
% of portfolio
0.96%
Previous 1.03%
Shares
7 transactions
Others Institutions Holding REGN
# of Institutions
1,483Shares Held
85.7MCall Options Held
908KPut Options Held
1.3M-
Vanguard Group Inc Valley Forge, PA8.99MShares$7.46 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$7.01 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY8.28MShares$6.87 Billion0.77% of portfolio
-
State Street Corp Boston, MA4.84MShares$4.02 Billion0.23% of portfolio
-
Capital World Investors Los Angeles, CA4.64MShares$3.85 Billion0.82% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $88.9B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...